JPWO2021183564A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021183564A5 JPWO2021183564A5 JP2022554368A JP2022554368A JPWO2021183564A5 JP WO2021183564 A5 JPWO2021183564 A5 JP WO2021183564A5 JP 2022554368 A JP2022554368 A JP 2022554368A JP 2022554368 A JP2022554368 A JP 2022554368A JP WO2021183564 A5 JPWO2021183564 A5 JP WO2021183564A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- nucleic acid
- acid molecule
- cancer
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062987191P | 2020-03-09 | 2020-03-09 | |
| US62/987,191 | 2020-03-09 | ||
| US202063073900P | 2020-09-02 | 2020-09-02 | |
| US63/073,900 | 2020-09-02 | ||
| PCT/US2021/021573 WO2021183564A1 (en) | 2020-03-09 | 2021-03-09 | Compositions and methods for inducing immune responses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023519173A JP2023519173A (ja) | 2023-05-10 |
| JPWO2021183564A5 true JPWO2021183564A5 (enExample) | 2024-03-19 |
Family
ID=77671984
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554681A Pending JP2023517644A (ja) | 2020-03-09 | 2021-03-09 | コロナウイルスワクチン組成物及び方法 |
| JP2022554368A Pending JP2023519173A (ja) | 2020-03-09 | 2021-03-09 | 免疫応答を誘導するための組成物及び方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554681A Pending JP2023517644A (ja) | 2020-03-09 | 2021-03-09 | コロナウイルスワクチン組成物及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US11759515B2 (enExample) |
| EP (2) | EP4117725A4 (enExample) |
| JP (2) | JP2023517644A (enExample) |
| AU (2) | AU2021236068A1 (enExample) |
| CA (2) | CA3171231A1 (enExample) |
| TW (1) | TW202200605A (enExample) |
| WO (2) | WO2021183563A1 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10526284B2 (en) * | 2016-12-21 | 2020-01-07 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
| US11679163B2 (en) | 2019-09-20 | 2023-06-20 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
| US11759515B2 (en) | 2020-03-09 | 2023-09-19 | Arcturus Therapeutics, Inc. | Compositions and methods for inducing immune responses |
| CA3172489A1 (en) | 2020-03-23 | 2021-09-30 | Amit KHANDHAR | Nanoemulsion compositions and methods for delivery of nra |
| WO2021213924A1 (en) | 2020-04-22 | 2021-10-28 | BioNTech SE | Coronavirus vaccine |
| WO2022011332A2 (en) * | 2020-07-10 | 2022-01-13 | Engimata, Inc | Immunogenic composition forming a vaccine, and a method for its manufacture |
| WO2022036170A1 (en) | 2020-08-14 | 2022-02-17 | Arcturus Therapeutics, Inc. | Method of lyophilizing lipid nanoparticles |
| SE544840C2 (en) * | 2020-09-28 | 2022-12-13 | Stora Enso Oyj | Method for the preparation of a bio-based carbon foam |
| AU2021360494A1 (en) | 2020-10-14 | 2023-05-18 | George Mason Research Foundation, Inc. | Ionizable lipids and methods of manufacture and use thereof |
| AU2021385572A1 (en) | 2020-11-25 | 2023-06-22 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids, and related methods of use |
| US20220356212A1 (en) * | 2021-03-26 | 2022-11-10 | Nanogen Pharmaceutical Biotechnology JSC | Modified spike protein and method of treatment |
| BR112024001911A2 (pt) * | 2021-07-30 | 2024-04-30 | Arcturus Therapeutics Inc | Vacinas de rna |
| CA3230031A1 (en) | 2021-09-03 | 2023-03-09 | Patrick Baumhof | Novel lipid nanoparticles for delivery of nucleic acids |
| EP4404962A2 (en) * | 2021-09-20 | 2024-07-31 | Cyanvac LLC | Piv5-based coronavirus vaccines and methods of use thereof |
| AU2022352486A1 (en) | 2021-09-22 | 2024-04-11 | Hdt Bio Corp. | Dried nanoparticle compositions |
| AU2022351009A1 (en) | 2021-09-22 | 2024-04-11 | Hdt Bio Corp. | Rna vaccines against infectious diseases |
| EP4404957A4 (en) | 2021-09-22 | 2025-08-06 | Hdt Bio Corp | CANCER THERAPY COMPOSITIONS AND THEIR USES |
| CA3232719A1 (en) | 2021-09-22 | 2023-03-30 | Steven Gregory REED | Sars-cov-2 rna vaccine compositions and methods of use |
| EP4413144A4 (en) * | 2021-10-07 | 2025-11-19 | Global Life Sciences Solutions Canada Ulc | RNA VACCINE LIPID NANOPARTICLES |
| AU2022381750A1 (en) * | 2021-11-03 | 2024-05-16 | Arcturus Therapeutics, Inc. | Lipid formulations containing nucleic acids and methods of treatment for cystic fibrosis |
| WO2023079472A2 (en) * | 2021-11-03 | 2023-05-11 | Kashiv Biosciences, Llc | Multicistron expression vector for covid-19 vaccine |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| US11510975B1 (en) * | 2021-11-29 | 2022-11-29 | Replicate Bioscience, Inc. | Compositions and methods for inducing ESR1, PI3K, HER2, and HER3 immune responses |
| CA3238159A1 (en) * | 2021-11-29 | 2023-06-01 | Hong Jiang | Sars cov-2 vaccine, associated polynucleotides, and methods of use |
| US20250041238A1 (en) * | 2021-12-23 | 2025-02-06 | Etherna Immunotherapies Nv | METHOD FOR LAGRE-SCALE PRODUCTION OF LARGE-SIZE LNPs |
| MX2024008082A (es) * | 2022-01-05 | 2024-07-15 | Helix Nanotechnologies Inc | Composiciones que comprenden la preprosecuencia del factor-alfa y sus usos. |
| US20250099614A1 (en) | 2022-01-28 | 2025-03-27 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| CN116916891A (zh) * | 2022-02-07 | 2023-10-20 | Seqirus公司 | 自我复制rna和其用途 |
| CN116768987A (zh) * | 2022-03-09 | 2023-09-19 | 中生复诺健生物科技(上海)有限公司 | 编码新型冠状病毒S蛋白的mRNA疫苗 |
| KR20250024759A (ko) * | 2022-04-19 | 2025-02-19 | 레플리케이트 바이오사이언스, 인크. | 변형된 서부 말 뇌염 바이러스 및 이의 용도 |
| CN114557971B (zh) * | 2022-04-25 | 2023-05-23 | 康希诺生物股份公司 | 一种核酸-脂质纳米颗粒的冷冻干燥保护剂及其制备方法和应用 |
| US12084703B2 (en) | 2022-05-12 | 2024-09-10 | SunVax mRNA Therapeutics Inc. | Synthetic self-amplifying mRNA molecules with secretion antigen and immunomodulator |
| WO2023221938A1 (zh) * | 2022-05-16 | 2023-11-23 | 上海行深生物科技有限公司 | 蛋白包裹自复制rna及其制备方法 |
| AU2023275780A1 (en) * | 2022-05-25 | 2024-12-05 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof |
| EP4531902A1 (en) | 2022-05-25 | 2025-04-09 | CureVac SE | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
| US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
| WO2024089229A1 (en) * | 2022-10-28 | 2024-05-02 | CureVac SE | Improved formulations comprising lipid-based carriers encapsulating rna |
| US12186388B2 (en) * | 2022-11-02 | 2025-01-07 | Centre For Virology, Vaccinology And Therapeutics Limited | Interferon-producing universal sarbecovirus vaccines, and uses thereof |
| WO2024163508A2 (en) * | 2023-01-31 | 2024-08-08 | Arcturus Therapeutics, Inc. | Methods and compositions for quadrivalent influenza vaccine |
| DE112024001143T5 (de) | 2023-03-08 | 2025-12-18 | CureVac SE | Neue lipid-nanopartikel-formeln für die abgabe von nukleinsäuren |
| WO2024230934A1 (en) | 2023-05-11 | 2024-11-14 | CureVac SE | Therapeutic nucleic acid for the treatment of ophthalmic diseases |
| WO2024249954A1 (en) * | 2023-05-31 | 2024-12-05 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025103803A1 (en) | 2023-11-13 | 2025-05-22 | CureVac SE | Immunotherapy against neuronal and brain tumors |
| WO2025104023A1 (en) * | 2023-11-13 | 2025-05-22 | Ziphius Nv | MODIFIED ALPHAVIRAL nsP3 |
| WO2025103414A1 (zh) * | 2023-11-14 | 2025-05-22 | 上海瑞宏迪医药有限公司 | 一种脂质纳米粒的制备方法和应用 |
| GB202400648D0 (en) * | 2024-01-17 | 2024-02-28 | Uea Enterprises Ltd | Protein replacement therapy |
| WO2025189168A1 (en) * | 2024-03-08 | 2025-09-12 | SunVax mRNA Therapeutics Inc. | Methods for cascade amplifications of therapeutic payloads (catp) & compositions for cancer immunotherapies and gene therapy |
| JP7657411B1 (ja) * | 2025-01-23 | 2025-04-07 | 医療法人すぎやま内科 | 乳がん細胞の増殖抑制剤及び乳がん治療剤 |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1432791B2 (en) | 2001-09-06 | 2013-10-23 | Alphavax, Inc. | Alphavirus replicon vector systems |
| JP5016305B2 (ja) | 2003-03-20 | 2012-09-05 | アルファヴァックス，インコーポレイテッド | 改良されたアルファウイルスレプリコンおよびヘルパー構築物 |
| CA2567254C (en) | 2004-05-18 | 2012-03-13 | Alphavax, Inc. | Tc-83-derived alphavirus vectors, particles and methods |
| EP1766034B1 (en) * | 2004-05-21 | 2014-03-19 | Novartis Vaccines and Diagnostics, Inc. | Alphavirus vectors for influenza virus vaccines |
| US7332322B2 (en) | 2004-09-14 | 2008-02-19 | Ilya Frolov | Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof |
| MY151062A (en) * | 2006-02-27 | 2014-03-31 | Univ Texas | Pseudoinfectious flavivirus and uses thereof |
| US8304529B2 (en) | 2006-07-28 | 2012-11-06 | Life Technologies Corporation | Dinucleotide MRNA cap analogs |
| WO2008119827A1 (en) * | 2007-04-02 | 2008-10-09 | Fit Biotech Oy | Transreplicase constructs |
| PL2947149T3 (pl) | 2007-06-21 | 2018-09-28 | Alphavax, Inc. | Kasety bez promotora do ekspresji alfawirusowych białek strukturalnych |
| WO2009058911A2 (en) | 2007-10-31 | 2009-05-07 | Applied Biosystems Inc. | Preparation and isolation of 5' capped mrna |
| US9234181B2 (en) | 2007-11-26 | 2016-01-12 | Novartis Ag | RNA expression cassette and cells for making alphavirus particles |
| CA2709875C (en) | 2008-01-02 | 2019-07-16 | Tekmira Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
| CA2721333C (en) | 2008-04-15 | 2020-12-01 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for nucleic acid delivery |
| EP2296702A1 (en) * | 2008-05-23 | 2011-03-23 | FIT Biotech Oy | Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant |
| PL2350043T3 (pl) | 2008-10-09 | 2014-09-30 | Tekmira Pharmaceuticals Corp | Ulepszone aminolipidy i sposoby dostarczania kwasów nukleinowych |
| WO2010048536A2 (en) | 2008-10-23 | 2010-04-29 | Alnylam Pharmaceuticals, Inc. | Processes for preparing lipids |
| WO2010054406A1 (en) | 2008-11-10 | 2010-05-14 | Alnylam Pharmaceuticals, Inc. | Novel lipids and compositions for the delivery of therapeutics |
| WO2010088537A2 (en) | 2009-01-29 | 2010-08-05 | Alnylam Pharmaceuticals, Inc. | Improved lipid formulation |
| NZ711583A (en) | 2009-05-05 | 2017-03-31 | Arbutus Biopharma Corp | Lipid compositions |
| KR102066189B1 (ko) | 2009-06-10 | 2020-01-14 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| US9101572B2 (en) * | 2009-12-31 | 2015-08-11 | Medigen, Inc. | Infectious DNA vaccines against chikungunya virus |
| SG186085A1 (en) | 2010-06-03 | 2013-01-30 | Alnylam Pharmaceuticals Inc | Biodegradable lipids for the delivery of active agents |
| HUE026646T2 (en) | 2010-07-06 | 2016-07-28 | Glaxosmithkline Biologicals Sa | Preferred liposomes containing lipids of PKA value for delivery of RNA |
| ES2586580T3 (es) * | 2010-07-06 | 2016-10-17 | Glaxosmithkline Biologicals Sa | Inmunización de mamíferos grandes con dosis bajas de ARN |
| HRP20161352T1 (hr) | 2010-07-06 | 2016-12-02 | Glaxosmithkline Biologicals Sa | Čestice nalik na virione za unos samoreplicirajućih molekula rna |
| RU2625546C2 (ru) * | 2010-07-06 | 2017-07-14 | Новартис Аг | Катионные эмульсии "масло-в-воде" |
| US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
| DK4226941T3 (da) | 2010-08-31 | 2024-12-02 | Glaxosmithkline Biologicals Sa | Pegylerede liposomer til levering af immunogen-kodende rna |
| EP4043040B1 (en) | 2010-08-31 | 2023-01-11 | GlaxoSmithKline Biologicals SA | Small liposomes for delivery of immunogen-encoding rna |
| WO2012170431A2 (en) * | 2011-06-06 | 2012-12-13 | Bluebird Bio, Inc. | Improved geneswitch systems |
| RU2649133C2 (ru) | 2011-07-06 | 2018-03-29 | Новартис Аг | Катионные эмульсии масло-в-воде |
| EP2729168A2 (en) | 2011-07-06 | 2014-05-14 | Novartis AG | Immunogenic compositions and uses thereof |
| US11896636B2 (en) | 2011-07-06 | 2024-02-13 | Glaxosmithkline Biologicals Sa | Immunogenic combination compositions and uses thereof |
| CN103764121A (zh) | 2011-07-06 | 2014-04-30 | 诺华股份有限公司 | 用于递送rna分子的具有有用n:p比的脂质体 |
| US20140255472A1 (en) | 2011-08-31 | 2014-09-11 | Andrew Geall | Pegylated liposomes for delivery of immunogen-encoding rna |
| US8961995B2 (en) | 2012-09-20 | 2015-02-24 | Uab Research Foundation | Methods and compositions for alphavirus replicons |
| WO2014170493A2 (en) | 2013-04-19 | 2014-10-23 | Novartis Ag | Alphavirus vector |
| EP3052511A4 (en) | 2013-10-02 | 2017-05-31 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
| MX2016005239A (es) | 2013-10-22 | 2016-08-12 | Shire Human Genetic Therapies | Tratamiento con acido ribonucleico mensajero para la fenilcetonuria. |
| ES2844208T3 (es) | 2014-03-25 | 2021-07-21 | Univ Yale | Usos de los factores inhibidores de la migración de macrófagos parásitos |
| EP3061826A1 (en) | 2015-02-27 | 2016-08-31 | Novartis AG | Flavivirus replicons |
| AU2016264027A1 (en) * | 2015-05-15 | 2017-08-31 | Curevac Ag | Prime-boost regimens involving administration of at least one mRNA construct |
| HUE065704T2 (hu) | 2015-09-21 | 2024-06-28 | Trilink Biotechnologies Llc | Készítmények és módszerek 5-sapkával ellátott RNS-ek szintetizálására |
| WO2017083356A1 (en) * | 2015-11-09 | 2017-05-18 | Immune Design Corp. | A retroviral vector for the administration and expression of replicon rna expressing heterologous nucleic acids |
| WO2017162266A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Rna replicon for versatile and efficient gene expression |
| US12257352B2 (en) | 2016-06-20 | 2025-03-25 | The Regents Of The University Of Michigan | Compositions and methods for delivery of biomacromolecule agents |
| WO2018010815A1 (en) | 2016-07-15 | 2018-01-18 | Biontech Rna Pharmaceuticals Gmbh | Formulation for administration of rna |
| MX2019004499A (es) | 2016-10-17 | 2019-11-18 | Janssen Pharmaceuticals Inc Star | Sistemas de replicón de virus recombinante y usos de estos. |
| WO2018075827A1 (en) | 2016-10-19 | 2018-04-26 | Arcturus Therapeutics, Inc. | Trinucleotide mrna cap analogs |
| IL317855A (en) | 2016-10-26 | 2025-02-01 | Acuitas Therapeutics Inc | mRNA vaccines with lipid nanoparticles |
| IL319407A (en) | 2016-11-23 | 2025-05-01 | Gritstone Bio Inc | Administration of neoantigens in the virus |
| AU2017372731B2 (en) | 2016-12-05 | 2024-05-23 | Janssen Pharmaceuticals, Inc. | Compositions and methods for enhancing gene expression |
| WO2018119163A1 (en) * | 2016-12-21 | 2018-06-28 | Payne Joseph E | Ionizable cationic lipid for rna delivery |
| US10383952B2 (en) * | 2016-12-21 | 2019-08-20 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
| US20190374650A1 (en) | 2017-02-22 | 2019-12-12 | The Regents Of The University Of Michigan | Compositions and methods for delivery of polymer/biomacromolecule conjugates |
| EP3589290A4 (en) | 2017-02-28 | 2020-12-30 | Arcturus Therapeutics, Inc. | Translatable molecules and synthesis thereof |
| JP2020518648A (ja) | 2017-05-08 | 2020-06-25 | グリットストーン オンコロジー インコーポレイテッド | アルファウイルス新生抗原ベクター |
| JP7284101B2 (ja) * | 2017-05-31 | 2023-05-30 | ウルトラジェニクス ファーマシューティカル インク． | 糖原病ｉｉｉ型のための治療薬 |
| US11015204B2 (en) | 2017-05-31 | 2021-05-25 | Arcturus Therapeutics, Inc. | Synthesis and structure of high potency RNA therapeutics |
| SG11202000019RA (en) * | 2017-07-28 | 2020-02-27 | Janssen Vaccines & Prevention Bv | Methods and compositions for heterologous reprna immunizations |
| CN118976103A (zh) | 2017-12-18 | 2024-11-19 | 英特维特国际股份有限公司 | 猪甲型流感病毒疫苗 |
| CA3089024A1 (en) * | 2018-01-19 | 2019-07-25 | Janssen Pharmaceuticals, Inc. | Induce and enhance immune responses using recombinant replicon systems |
| WO2020014654A1 (en) | 2018-07-13 | 2020-01-16 | The Trustees Of Indiana University | Recombinant rotavirus expression system and recombinant rotaviruses |
| CA3109165A1 (en) | 2018-08-17 | 2020-02-20 | Glaxosmithkline Biologicals Sa | Immunogenic compositions and uses thereof |
| US11026894B2 (en) | 2019-01-10 | 2021-06-08 | Massachusetts Institute Of Technology | Lipid nanoparticles and use thereof to deliver RNA polynucleotides |
| KR20220018960A (ko) | 2019-03-19 | 2022-02-15 | 아크투루스 쎄라퓨틱스, 인크. | 지질-캡슐화된 rna 나노입자 제조 방법 |
| GB201908729D0 (en) | 2019-06-18 | 2019-07-31 | Imp College Innovations Ltd | RNA construct |
| WO2020254535A1 (en) | 2019-06-18 | 2020-12-24 | Curevac Ag | Rotavirus mrna vaccine |
| MA56535A (fr) | 2019-06-20 | 2022-04-27 | Janssen Sciences Ireland Unlimited Co | Molécules d'arn à auto-réplication pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées |
| HRP20241379T1 (hr) | 2019-09-30 | 2024-12-20 | Gilead Sciences, Inc. | Cjepiva za hbv i postupci za liječenje hbv |
| WO2021067598A1 (en) * | 2019-10-04 | 2021-04-08 | Ultragenyx Pharmaceutical Inc. | Methods for improved therapeutic use of recombinant aav |
| US12194089B2 (en) * | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| WO2021160346A1 (en) * | 2020-02-13 | 2021-08-19 | Institut Pasteur | Nucleic acid vaccine against the sars-cov-2 coronavirus |
| CA3169889A1 (en) * | 2020-03-03 | 2021-09-10 | Arcturus Therapeutics, Inc. | Compositions and methods for the treatment of ornithine transcarbamylase deficiency |
| US11759515B2 (en) | 2020-03-09 | 2023-09-19 | Arcturus Therapeutics, Inc. | Compositions and methods for inducing immune responses |
| BR112024001911A2 (pt) | 2021-07-30 | 2024-04-30 | Arcturus Therapeutics Inc | Vacinas de rna |
-
2021
- 2021-03-09 US US17/196,890 patent/US11759515B2/en active Active
- 2021-03-09 WO PCT/US2021/021572 patent/WO2021183563A1/en not_active Ceased
- 2021-03-09 US US17/196,889 patent/US11744887B2/en active Active
- 2021-03-09 JP JP2022554681A patent/JP2023517644A/ja active Pending
- 2021-03-09 CA CA3171231A patent/CA3171231A1/en active Pending
- 2021-03-09 JP JP2022554368A patent/JP2023519173A/ja active Pending
- 2021-03-09 AU AU2021236068A patent/AU2021236068A1/en active Pending
- 2021-03-09 AU AU2021233816A patent/AU2021233816A1/en active Pending
- 2021-03-09 WO PCT/US2021/021573 patent/WO2021183564A1/en not_active Ceased
- 2021-03-09 TW TW110108383A patent/TW202200605A/zh unknown
- 2021-03-09 EP EP21767978.6A patent/EP4117725A4/en active Pending
- 2021-03-09 CA CA3171219A patent/CA3171219A1/en active Pending
- 2021-03-09 EP EP21768525.4A patent/EP4117720A4/en active Pending
-
2023
- 2023-06-30 US US18/345,893 patent/US12220455B2/en active Active
- 2023-07-12 US US18/351,392 patent/US12390524B2/en active Active
-
2024
- 2024-12-04 US US18/969,110 patent/US20250161434A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021183564A5 (enExample) | ||
| ES2223051T3 (es) | Vectores de adnc de alfavirus. | |
| JP7613685B2 (ja) | 新規ｒｓｖ ｒｎａ分子及びワクチン接種用組成物 | |
| Quetglas et al. | Alphavirus vectors for cancer therapy | |
| JP2018186815A5 (enExample) | ||
| JP2022160401A (ja) | Ｈｐｖワクチン | |
| JP2022160401A5 (enExample) | ||
| JP2015527296A5 (enExample) | ||
| Lundstrom | Alphavirus vectors for vaccine production and gene therapy | |
| WO2022166959A1 (zh) | 顺式复制子构建体 | |
| Polo et al. | Virus-based vectors for human vaccine applications | |
| JP2020510426A5 (enExample) | ||
| CN106459997A (zh) | 用于疫苗应用的高效价病毒样囊泡的进化 | |
| JP2004501646A5 (enExample) | ||
| WO2008007581A1 (en) | Non-replicating paramyxoviridae virus vector | |
| JP7298906B2 (ja) | 光制御性のウイルスタンパク質、その遺伝子、及びその遺伝子を含むウイルスベクター | |
| FI4305181T3 (fi) | Minimaalinen nefriinipromoottori | |
| JP2005508610A (ja) | 異種タンパク質の製造に有用なプラス鎖ｒｎａウイルスゲノムに由来するレプリコン | |
| ES2585735T3 (es) | Nuevas proteínas de fusión y su aplicación para la preparación de vacunas contra la hepatitis C | |
| Lundstrom | Semliki Forest virus vectors for gene therapy | |
| Zajakina et al. | Application of alphaviral vectors for immunomodulation in cancer therapy | |
| Lundstrom | Application of viruses for gene therapy and vaccine development | |
| Lundstrom | Viral Vector-Based Cancer Vaccines | |
| Von Messling et al. | Toward novel vaccines and therapies based on negative-strand RNA viruses | |
| RU2398875C2 (ru) | Вирусные частицы, содержащие вектор, происходящий из альфавируса, и способ получения указанной вирусной частицы |